This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis.
The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.

Start Date01 Aug 2026

Sponsor / Collaborator

The University of California, San Francisco

NCT07620561

/ Not yet recruitingPhase 2IIT

Evaluating the Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients: A 24-Week Study

The purpose of this study is to evaluate the effectiveness of lebrikizumab in treating adults with moderate-to-severe Prurigo Nodularis (PN).

Start Date01 Jun 2026

Sponsor / Collaborator

University of Maryland Baltimore

[+1]

CTIS2025-524435-39-00

/ Not yet recruitingPhase 2IIT

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 250 mg lebrikizumab in patients with localized scleroderma (LEMO)

Start Date30 Apr 2026

Sponsor / Collaborator-

100 Clinical Results associated with Lebrikizumab

100 Translational Medicine associated with Lebrikizumab

100 Patents (Medical) associated with Lebrikizumab

272

Literatures (Medical) associated with Lebrikizumab

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

From signal to strategy: a disproportionality analysis of dupilumab-associated rosacea in FAERS with a summary of reported clinical cases

Review

Author: Yang, Xuefan ; Ruan, Dandan ; Chen, Xiang ; Li, Sitong ; Lin, Jiacheng ; Qiu, Xinlan ; Li, Jiaqi ; Ju, Qiang ; Mo, Xiaohui

PURPOSE:

Emerging evidence suggests rosacea as a recognizable adverse event during dupilumab therapy. This study aimed to investigate the potential association between dupilumab and rosacea using pharmacovigilance data and to characterize the clinical features of dupilumab-associated rosacea (DAR) through a review of reported cases.

MATERIALS AND METHODS:

We utilized the FDA Adverse Event Reporting System (FAERS) database (2017-2024) to identify disproportionality signals using four methods: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Information Component (IC), and Empirical Bayesian Geometric Mean (EBGM). To contextualize these findings, we performed a focused narrative review of 8 publications comprising 10 DAR cases with extractable individual data.

RESULTS:

A significant disproportionality signal was identified across all four methods (ROR 3.873; PRR 3.872; IC 1.865 with IC025 1.653; EBGM 3.642), with reports predominantly in adults and females. In the case review, a consistent phenotype emerged: papulopustules on persistent centrofacial erythema with frequent burning; facial predominance with occasional extension to neck, scalp, or upper trunk; frequent Demodex detection by scraping, KOH, or in vivo imaging; and occasional granulomatous histology. Onset ranged from approximately 2 weeks to 21 months, including one post-discontinuation case. Most patients improved with rosacea-directed therapy (topical ivermectin or metronidazole; anti-inflammatory-dose doxycycline). However, dechallenge or rechallenge patterns and the need for dose-interval extension, temporary interruption, or switching biologic (e.g., lebrikizumab, upadacitinib) in a subset support a drug-related pattern at the reporting level.

CONCLUSIONS:

DAR represents a distinct clinical entity from dupilumab-associated head and neck dermatitis, which is eczematous and typically responds to antifungals or calcineurin inhibitors. While disproportionality signals indicate association rather than incidence or causality and are subject to reporting bias, clinicians should be aware of this potential adverse event to ensure appropriate management.

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitis

Article

Author: Gudjonsson, Johann E. ; Okragly, Angela ; Rueda, Maria Jose ; Eyerich, Kilian ; Armstrong, April W. ; Elmaraghy, Hany ; Xu, Chenjia ; Moser, Brian A. ; Bieber, Thomas ; Gallo, Gaia ; Silverberg, Jonathan I. ; Uluckan, Ozge ; Nickoloff, Brian J. ; Wolf, Eric ; Natalie, Chitra R.

AIM OF THE STUDY:

Lebrikizumab monotherapy demonstrated efficacy for adults and adolescents with moderate-to-severe atopic dermatitis (AD). This study aims to evaluate the relationship between lebrikizumab serum levels and stable deep response after treatment cessation in Week 16-responder patients who maintained stable EASI 90 response post-induction up to Week 52.

MATERIALS AND METHODS:

Analysis was pooled from two identically designed, randomized, double-blind, placebo-controlled, phase 3 trials, ADvocate1 (NCT04146363; conducted from September 24, 2019, to May 3, 2022) and ADvocate2 (NCT04178967; conducted from October 29, 2019, to April 28, 2022). The analysis subgroup includes those patients who were Week-16 responders, have been re-randomized to receive placebo (withdrawal arm), and maintained a stable EASI 90 response for at least 80% of visits up to 52 weeks, without rescue medication. Serum lebrikizumab was measured at Weeks 4, 16, 32, and 52.

RESULTS:

During withdrawal, 28% of responders (17/60) maintained a stable EASI 90 response with no or minimal fluctuations, including at Week 52, without rescue medication. Mean serum lebrikizumab decreased by 92% and over 99% from Week 16 to Weeks 32 and 52, respectively (Week 16 = 92.4 μg/mL; Week 32 = 7.3 μg/mL; Week 52 = 0.15 μg/mL).

CONCLUSION:

Lebrikizumab demonstrated off-therapy maintenance of response in an AD patient subset for at least 38 weeks post-discontinuation.

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Raising the bar of efficacy in Atopic Dermatitis: deep response in week 16 responders treated with lebrikizumab over 2 years

Article

Author: Xu, Chenjia ; Biedermann, Tilo ; Figueras, Ignasi ; Agell, Helena ; Simpson, Eric ; Kircik, Leon ; Hu, Chaoran ; Pierce, Evangeline ; Gallo, Gaia ; Vestergaard, Christian ; Chovatiya, Raj ; Casillas, Marta ; Ding, Yuxin

BACKGROUND:

Lebrikizumab, a high-affinity monoclonal antibody targeting interleukin-13, effectively treats moderate-to-severe atopic dermatitis (AD).

METHODS:

Lebrikizumab-treated patients in ADvocate1&2 achieving per-protocol response-IGA (0,1) or EASI 75 at Week 16-were re-randomized 2:2:1 to lebrikizumab 250 mg every 2 weeks (Q2W), Q4W, or placebo (lebrikizumab withdrawal). Patients completing Week 52 could enroll in the extension study, ADjoin. Deep response was defined as IGA (0), EASI 100, or Pruritus Numerical Rating Scale score 0 or 1 (NRS [0,1]). This analysis reports as-observed data.

RESULTS AND CONCLUSIONS:

From Week 16-104, among IGA (0,1) responders at Week 16, increased proportions of patients achieved IGA (0) with lebrikizumab Q2W (33.8% [Nx = 77] to 52.3% [Nx = 44]) and Q4W (29.9% [Nx = 77] to 45.5% [Nx = 55]); among EASI 75 responders at Week 16, increased proportions of patients achieved EASI 100 with lebrikizumab Q2W (21.4% [Nx = 112] to 39.7% [Nx = 68]) and Q4W (20.0% [Nx = 115] to 41.3% [Nx = 80]); and among per-protocol responders, increased proportions of patients reported Pruritus NRS (0,1) with lebrikizumab Q2W (35.2% [Nx = 108] to 57.4% [Nx = 61]) and Q4W (34.2% [Nx = 114] to 55.4% [Nx = 65]). Continued lebrikizumab treatment for 2 years resulted in approximately half of per-protocol responders achieving complete skin clearance (IGA 0) and itch relief, raising the bar of treatment goals for AD patients.

201

News (Medical) associated with Lebrikizumab

13 Aug 2026

·www.globenewswire.com

New MotherToBaby Study Targets Pregnancy Data Gap for Newer Eczema Treatment

The FDA has determined that human pregnancy data for Ebglyss® remain insufficient. By enrolling U.S. and Canadian participants, this study will help generate the evidence needed to inform future treatment decisions.San Diego, CA, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Pregnant women with moderate-to-severe eczema and their healthcare providers face a difficult evidence gap: how to make treatment decisions when human pregnancy data for newer therapies remain limited. MotherToBaby has launched a new observational pregnancy study to learn more about Ebglyss® (lebrikizumab) when used during pregnancy to treat moderate-to-severe atopic dermatitis (eczema). The study is now enrolling pregnant women across the United States and Canada. The research is part of MotherToBaby Pregnancy Studies’ ongoing commitment to generating evidence that helps patients and healthcare providers make informed decisions about medication use during pregnancy. The study is led by internationally recognized epidemiologist Christina D. Chambers, PhD, MPH, Professor of Pediatrics at the UC San Diego’s School of Medicine and one of the world's leading experts in pregnancy exposure research. Dr. Chambers has spent more than three decades leading landmark observational studies that have advanced understanding of medication safety during pregnancy. Atopic dermatitis affects many women during their reproductive years, and managing the condition during pregnancy can be challenging. While effective treatment is important for the health and well-being of the pregnant woman, information about the use of newer medications during pregnancy remains limited. This study aims to help fill that knowledge gap. The MotherToBaby Ebglyss Pregnancy Study will follow participants throughout pregnancy and after delivery to better understand pregnancy and infant outcomes associated with Ebglyss exposure. Researchers will compare pregnancy outcomes among women who used at least one dose of Ebglyss a few months before or during pregnancy with those of women who have atopic dermatitis and received other systemic treatments, phototherapy, or no systemic treatment during pregnancy. These comparison groups will help researchers better understand the effects of both the medication and the underlying condition. The study is observational, meaning participants will not be asked to take any study medication or change the treatment recommended by their healthcare providers. Instead, researchers collect health information through interviews and medical record review, with participants' permission, to better understand real-world pregnancy outcomes. Observational research plays a critical role in generating evidence about medication safety during pregnancy because pregnant women are rarely included in clinical trials. "Every participant who shares their experience helps expand the evidence available to support informed eczema treatment decisions during pregnancy," said Christina D. Chambers, PhD, MPH. "Our goal is to provide reliable, science-based information that benefits patients, healthcare providers, and future families." MotherToBaby is seeking pregnant individuals across the United States and Canada who: Are currently pregnantHave used Ebglyss during pregnancyHave been diagnosed with atopic dermatitis (eczema) with or without treatment for our comparison group Participation is voluntary, and all information is kept confidential. The study is expected to continue enrolling participants through 2033, helping build one of the largest sources of information on pregnancy outcomes associated with Ebglyss and atopic dermatitis treatment. Individuals interested in participating or learning more about the study can contact MotherToBaby at 877.311.8972 or visit https://mothertobaby.org/ongoing-study/ebglyss-lebrikizumab-lbkz. About MotherToBaby MotherToBaby is the nation's leading source of evidence-based information on medications and other exposures during pregnancy and while breastfeeding. MotherToBaby provides free, expert information to the public and healthcare providers through phone, text, chat, and email, while conducting pregnancy studies that help improve knowledge about the safety of medications and vaccines during pregnancy. Media Contact: Nicole Chavez, nchavez@mothertobaby.org, 619-368-3259

Clinical Study

11 Aug 2026

·firstwordpharma.com

Infinimmune bags $75M for atopic dermatitis antibody duo

Fresh off a drug discovery deal with Merck & Co., California-based startup Infinimmune pocketed fresh funding on Tuesday to advance its own pipeline. The $75-million series A, co-led by Regeneron Ventures and Playground Global, will help the biotech move its two lead antibodies into the clinic for atopic dermatitis (AD) next year. A slew of new investors, including RA Capital Management, Goldcrest Capital, Forge Life Science Partners and Godfrey Capital, also participated in the round, as did existing investors Merck Global Health Innovation Fund, Everbright Biofund, Civilization Ventures and Pear VC. The financing, which comes less than four years after it raised $12 million in seed funding, was "driven by the rapid progress of Infinimmune’s pipeline," CEO and co-founder Wyatt McDonnell told FirstWord. Antibody engine"Since its seed financing, the company has validated its human-first discovery platform, generated a portfolio of differentiated therapeutic antibodies and entered a multi-target collaboration with Merck," he detailed. Inked in March, the deal with Merck is worth up to $838 million in biobucks and is centred around Infinimmune's Anthrobody discovery platform, a "library-on-B-cell" system that screens millions of individual memory B-cells across hundreds of potential targets at once, as well as its "antibody language" AI model, GLIMPSE. "Infinimmune begins with antibodies generated and selected naturally by the human immune system rather than relying exclusively on synthetic libraries or engineering antibodies from non-human starting points," McDonnell said. Then, alongside laboratory testing, Infinimmune uses GLIPSE to optimise antibody candidates for potency, half-life, manufacturability and other therapeutic characteristics. "This approach enables Infinimmune to start with antibodies that have already been selected through human immune biology and then improve the properties needed to create a medicine," McDonnell explained. The biotech's two lead candidates were both born from this process. IFX-101 is a potentially first-in-class IL-22–targeting mAb, while IFX-201 could be a best-in-class IL-13 inhibitor; both are being developed for AD. Advantages in AD?According to McDonnell, despite treatment advances, many patients with moderate-to-severe disease are unable to adequately or durably manage the condition, leaving room in the treatment landscape for convenient therapies capable of clearing skin in a long-lasting manner and improving quality of life. With IFX-201, Infinimmune is looking to differentiate its candidate from existing IL-13 blockers, like Ebglyss (lebrikizumab-lbkz), by improving upon potency, dosing frequency and developability. Other potential competitors in the space include Sanofi and Regeneron's megablockbuster Dupixent (dupilumab), which targets IL-4 in addition to IL-13."Infinimmune’s objective is never to simply engage a validated target. It is to produce an antibody with a meaningfully better therapeutic profile," McDonnell said. The biotech is also aiming to be the first to bring an IL-22 inhibitor to market with IFX-101. While a well-validated target — IL-22 is a cytokine associated with abnormal proliferation of keratinocytes, barrier dysfunction and chronic skin inflammation — drugmakers have struggled to generate a sufficiently potent antibody with the necessary pharmacologic properties to function therapeutically. "Earlier clinical efforts helped validate the target biology, but did not produce the combination of neutralisation potency, pharmacokinetic profile, or dosing convenience needed to sustain deep pathway suppression in the correct patient population," McDonnell said. "IFX-101’s potent inhibition of IL-22 signalling, extended half-life, and human-derived origin could address several of these limitations."

06 Aug 2026

·www.genohopebio.com

Lilly Reports Second-quarter 2026 Financial Results, Raises Full-year Guidance, And Highlights Continued Growth And Pipeline Progress

Aug 06, 2026 Leave a message Revenue in Q2 2026 increased 48% to $23.0 billion driven primarily by Mounjaro and Zepbound volume. Q2 2026 EPS increased by 26% to $7.94 on a reported basis and increased by 33% to $8.38 on a non-GAAP basis. Q2 2026 reported and non-GAAP EPS included $3.03 of acquired IPR&D charges compared to $0.14 in Q2 2025. Increased 2026 full-year revenue guidance to be in the range of $85.0 billion to $87.0 billion and raised underlying non-GAAP EPS guidance for the full year by $2.78 at the midpoint, which was more than offset by $3.03 of acquired IPR&D charges from Q2 business development activity, resulting in an updated range of $35.50 to $36.50. Regulatory progress included U.S. FDA approval of Ebglyss for one maintenance dose every eight weeks in moderate-to-severe atopic dermatitis, European Commission approval of Jaypirca as monotherapy for adults with chronic lymphocytic leukemia across all lines of therapy, and the submission for orforglipron for type 2 diabetes in the U.S. Pipeline highlights included positive data from three additional Phase 3 trials of retatrutide in obesity. The clinical data package is now complete to support global registrations for obesity, obstructive sleep apnea, and knee osteoarthritis pain, with plans to submit a Biologics License Application to the U.S. FDA in the first quarter of 2027. Business development activity in Q2 2026 included the completed acquisitions of Orna Therapeutics, Inc., Ajax Therapeutics, Inc., Centessa Pharmaceuticals plc. and Kelonia Therapeutics, Inc. Subsequent to quarter end, we completed three acquisitions to build an infectious disease portfolio and entered into an agreement to acquire AtaiBeckley, Inc. Committed an additional $4.5 billion to expand Indiana manufacturing sites. INDIANAPOLIS, Aug. 5, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the second quarter of 2026 and provided updated 2026 financial guidance. "Lilly's momentum continues, as we delivered 48% revenue growth and raised our full-year guidance," said David A. Ricks, Lilly chair and CEO. "At the same time, Lilly is building for the future. With our next-generation weight-loss medicine retatrutide and its complete clinical data package in hand, new manufacturing capacity coming online, and exciting new assets entering our pipeline through business development, Lilly's future, after 150 years, has never been brighter." Second-Quarter Reported Results In Q2 2026, worldwide revenue was $23.0 billion, an increase of 48% compared with Q2 2025, driven by a 60% increase in volume, partially offset by a 13% decrease in realized prices. Key Products1 revenue grew to $15.7 billion in Q2 2026, led by Mounjaro and Zepbound. Key Products revenue in the Immunology, Oncology, and Neuroscience therapeutic areas grew 121% in Q2 2026 compared to Q2 2025. Revenue in the U.S. increased 33% to $14.4 billion, driven by a 37% increase in volume, partially offset by a 3% decrease in realized prices. The increase in U.S. volume was driven by Zepbound and Mounjaro. The decline in realized prices was primarily driven by Zepbound and Mounjaro, partially offset by adjustments to estimates for rebates and discounts primarily driven by Trulicity, Zepbound, and Mounjaro. Excluding these adjustments, U.S. price would have declined by approximately 9%. Revenue outside the U.S. increased 80% to $8.6 billion, driven by a 113% increase in volume, partially offset by a 36% decrease in realized prices. The lower realized prices outside the U.S. were driven primarily by the addition of Mounjaro to the National Reimbursement Drug List (NRDL) in China. The volume increase outside the U.S. was driven by Mounjaro. Jardiance revenue outside the U.S. included a sales-based milestone of $250 million in Q2 2026, associated with the company's collaboration with Boehringer Ingelheim. 1 The Company currently defines Key Products as Ebglyss, Foundayo (added Q2 2026), Inluriyo, Jaypirca, Kisunla, Mounjaro, Omvoh, and Zepbound. Gross margin increased 50% to $19.7 billion in Q2 2026. Gross margin as a percent of revenue was 85.8%, an increase of 1.5 percentage points versus the same quarter last year. The increase was primarily driven by improved cost of production and favorable product mix, partially offset by lower realized prices. In Q2 2026, research and development expenses increased 14% to $3.8 billion, or 17% of revenue, driven by continued investments in the company's early and late-stage portfolio. Marketing, selling, and administrative expenses increased 25% to $3.4 billion in Q2 2026, primarily driven by promotional efforts supporting ongoing and planned launches. In Q2 2026, the company recognized acquired in-process research and development (IPR&D) charges of $2.8 billion compared with $154 million in Q2 2025. The Q2 2026 charges primarily related to the acquisitions of Orna Therapeutics, Inc. and Ajax Therapeutics, Inc. Asset impairment, restructuring and other special charges of $703 million in Q2 2026 were primarily related to the accelerated vesting of employee equity awards and other acquisition and integration costs associated with the closing of our acquisitions of Kelonia Therapeutics, Inc. and Centessa Pharmaceuticals plc. In Q2 2025, there were no asset impairment, restructuring and other special charges. The effective tax rate was 23.3% in Q2 2026 compared with 16.5% in Q2 2025, primarily driven by the unfavorable tax impact of non-deductible acquired IPR&D charges in Q2 2026. In Q2 2026, net income and earnings per share (EPS) were $7.1 billion and $7.94, respectively, compared with net income of $5.7 billion and EPS of $6.29 in Q2 2025. EPS in Q2 2026 and Q2 2025 included acquired IPR&D charges of $3.03 and $0.14, respectively. Second-Quarter Non-GAAP Measures On a non-GAAP basis, Q2 2026 gross margin increased 50% to $19.8 billion. Gross margin as a percent of revenue was 86.3%, an increase of 1.3 percentage points versus the same quarter last year. The increase was primarily driven by improved cost of production and favorable product mix, partially offset by lower realized prices. The non-GAAP effective tax rate was 22.2% in Q2 2026 compared with 16.5% in Q2 2025, primarily driven by the unfavorable tax impact of non-deductible acquired IPR&D charges in Q2 2026. On a non-GAAP basis, Q2 2026 net income and EPS were $7.5 billion and $8.38, respectively, compared with net income of $5.7 billion and EPS of $6.31 in Q2 2025. Non-GAAP EPS in Q2 2026 and Q2 2025 included acquired IPR&D charges of $3.03 and $0.14, respectively. Mounjaro For Q2 2026, worldwide Mounjaro revenue increased 91% to $9.9 billion. U.S. revenue was $4.8 billion, an increase of 45%, reflecting strong demand, partially offset by lower realized prices. Lower realized prices were partially offset by adjustments to estimates for rebates and discounts. Revenue outside the U.S. increased 172% to $5.2 billion primarily driven by volume growth, partially offset by lower realized prices driven by the addition of Mounjaro to the NRDL in Q1 2026. Zepbound For Q2 2026, U.S. Zepbound revenue increased 44% to $4.9 billion, primarily driven by strong demand, partially offset by lower realized prices, including previously announced reductions in cash-pay prices. Lower realized prices were partially offset by adjustments to estimates for rebates and discounts. GenoHope Biotech Ltd. A leading manufacturer of GLP-1 API Approal by FDA Welcome any Inquiry WhatsApp/Tel:+8613833133635 Email:info@genohopebio.com Send Inquiry

Drug ApprovalAcquisitionFinancial StatementPhase 3Clinical Result

100 Deals associated with Lebrikizumab

External Link

KEGG	Wiki	ATC	Drug Bank
D09633	Lebrikizumab	-	DB11914

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Dermatitis, Atopic	European Union	Almirall SA	16 Nov 2023
Dermatitis, Atopic	Iceland	Almirall SA	16 Nov 2023
Dermatitis, Atopic	Liechtenstein	Almirall SA	16 Nov 2023
Dermatitis, Atopic	Norway	Almirall SA	16 Nov 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Nummular eczema	Phase 3	Germany	Almirall SA	24 Apr 2026
Chronic rhinosinusitis with nasal polyps	Phase 3	United States	Eli Lilly & Co.	29 Apr 2024
Chronic rhinosinusitis with nasal polyps	Phase 3	China	Eli Lilly & Co.	29 Apr 2024
Chronic rhinosinusitis with nasal polyps	Phase 3	Japan	Eli Lilly & Co.	29 Apr 2024
Chronic rhinosinusitis with nasal polyps	Phase 3	Argentina	Eli Lilly & Co.	29 Apr 2024
Chronic rhinosinusitis with nasal polyps	Phase 3	Belgium	Eli Lilly & Co.	29 Apr 2024
Chronic rhinosinusitis with nasal polyps	Phase 3	Bulgaria	Eli Lilly & Co.	29 Apr 2024
Chronic rhinosinusitis with nasal polyps	Phase 3	Canada	Eli Lilly & Co.	29 Apr 2024
Chronic rhinosinusitis with nasal polyps	Phase 3	Denmark	Eli Lilly & Co.	29 Apr 2024
Chronic rhinosinusitis with nasal polyps	Phase 3	Finland	Eli Lilly & Co.	29 Apr 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05990725 (ADhope, CTgov)	Phase 3	Eczema \| Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	260	Lebrikizumab	vilxvwhala = yfgoafelpm ffoofjhdwv (dqirspzmsm, yowfarjavd - iakoieeolf) View more	-	17 Jul 2026
NCT02104674 (CTgov)	Phase 3	Asthma	313	Lebrikizumab (Double-Blind: Lebrikizumab)	ylrhsejjsa(hazymkgcfs) = awuvbhcglv vuseqskmuz (rzutpigbra, 0.033) View more	-	17 Jul 2026
NCT02104674 (CTgov)	Phase 3	Asthma	313	Placebo (Double-Blind: Placebo)	ylrhsejjsa(hazymkgcfs) = ifndldltvg vuseqskmuz (rzutpigbra, 0.032) View more	-	17 Jul 2026
NCT01875003 (ACOUSTICS, CTgov)	Phase 3	Asthma	346	Placebo+Lebrikizumab	shvdsrdmwq = fovsdhfszr tjrjbyzcha (leerlmfmin, dubhdvjcmi - fxexrpqhjc) View more	-	30 Jun 2026
NCT04392154 (ADjoin, Pubmed \| Dermatol Ther (Heidelb))	Phase 3	Dermatitis, Atopic	267	Lebrikizumab 250 mg Q2W	worgchvicj(ztkromdlnd) = Most adverse events (AEs) were mild (29.2%) or moderate (33.3%) in severity. cjgktcvdvq (kgonpnfxzu )	Positive	19 Jun 2026
AAD2026	Not Applicable	Dermatitis, Atopic	1,092	Lebrikizumab	wnidoizjfr(kgeytygano) = yzwqgonbqa ynmfauytog (dovuktdnjh ) View more	Positive	27 Mar 2026
AAD2026	Not Applicable	Dermatitis, Atopic	1,092	Nemolizumab	wnidoizjfr(kgeytygano) = ymmkipjhyj ynmfauytog (dovuktdnjh ) View more	Positive	27 Mar 2026
NCT05372419 (ADmirable, AAD2026)	Phase 3	Dermatitis, Atopic	90	Lebrikizumab 500mg at baseline and Week 2, then 250mg every 2 weeks until Week 24; responders switched to 250mg every 4 weeks at Week 16	hsvhdlsbww(dlcqkpbqol) = nojdqjqgba nxpcdfsdon (slasgezrwv ) View more	Positive	27 Mar 2026
NCT05372419 (ADmirable, AAD2026)	Phase 3	Dermatitis, Atopic	90	Lebrikizumab 250 mg	unluvbocxv(saqwoohdgb) = uympbaurfv spvornrxva (ncsmhfbweb ) View more	Positive	27 Mar 2026
AAD2026	Not Applicable	Dermatitis, Atopic	42	Lebrikizumab	oxmnzgmhvd(ecdjiwfcve) = zmjxwhgyeu cnrvfanxrq (aldvuqeocn ) View more	Positive	27 Mar 2026
ADlong (AAD2026)	Not Applicable	Moderate Atopic Dermatitis	174	Lebrikizumab 250mg (Q4W or Q2W)	tbcysqnbnp(ibvqllxwjk) = sjjdhvcjba qhvfplamcw (qlntcogceq ) View more	Positive	27 Mar 2026
AD-LIFE (AAD2026)	Not Applicable	Dermatitis, Atopic	100	Lebrikizumab (pretreated with AdvST)	icavnbkvaj(zoqybhlcdn) = qpvkxldiys nkztvsbrye (gogdqoqdja ) View more	Positive	27 Mar 2026
AD-LIFE (AAD2026)	Not Applicable	Dermatitis, Atopic	100	Lebrikizumab (AdvSTn)	icavnbkvaj(zoqybhlcdn) = mdqesoxdod nkztvsbrye (gogdqoqdja ) View more	Positive	27 Mar 2026

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis